MAGEA4 and synovial sarcoma: A second TCR-T targeting the cancer-testis antigen melanoma-associated antigen 4 (MAGE-A4), afamitresgene autoleucel (afami-cel, ADP-A2M4), was recently approved based on phase 2 data reporting an overall response rate of 39% (19/52) in patients with advanced synovial sarcoma and myxoid round cell liposarcoma.4